Pharming Group
PHAR
Pharming Group (PHAR) news
Recent news
Pharming presents positive phase II topline data for leniolisib
AInvest Wire · 1d agoPharming Group N.V. - Topline results from separate phase II trial in cvid expected in November
AInvest Wire · 1d agoPharming Group N.V. - Leniolisib was generally well-tolerated across all 4 genotypes
AInvest Wire · 1d agoPharming Group N.V - All phase II leniolisib study completers enrolled in three-year extension study
AInvest Wire · 1d agoPharming Group N.V - Improvement in liver stiffness observed in phase II leniolisib trial
AInvest Wire · 1d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.